These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

231 related articles for article (PubMed ID: 36051631)

  • 1. Open questions on the management of targeted therapies for the treatment of systemic sclerosis-interstitial lung disease: results of a EUSTAR survey based on a systemic literature review.
    Campochiaro C; Lazzaroni MG; Bruni C; Zanatta E; De Luca G; Matucci-Cerinic M
    Ther Adv Musculoskelet Dis; 2022; 14():1759720X221116408. PubMed ID: 36051631
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Systemic-Sclerosis-Related Interstitial Lung Disease: A Review of the Literature and Recommended Approach for Clinical Pharmacists.
    Ferrari HM; Kale-Pradhan P; Konja J; Dierker M; Martirosov AL
    Ann Pharmacother; 2023 Dec; ():10600280231213672. PubMed ID: 38095621
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Systemic Sclerosis Associated Interstitial Lung Disease and Nintedanib: A Rare Disease and a Promising Drug.
    Kafle S; Thapa Magar M; Patel P; Poudel A; Cancarevic I
    Cureus; 2021 Jul; 13(7):e16404. PubMed ID: 34414042
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and safety of biological drugs in interstitial lung disease associated with connective tissue diseases.
    Vicente-Rabaneda EF; Serra López-Matencio JM; Ancochea J; Blanco R; González-Gay MÁ; Castañeda S
    Expert Opin Drug Saf; 2022 Mar; 21(3):311-333. PubMed ID: 34433372
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Should we use nintedanib as early therapy in patients with SSc-ILD?
    Zanatta E; Moccaldi B; Szucs G; Spagnolo P
    Autoimmun Rev; 2024 Jan; 23(1):103463. PubMed ID: 37844857
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of nintedanib-induced gastrointestinal adverse events between patients with systemic sclerosis-associated interstitial lung disease and idiopathic interstitial pneumonias.
    Imai M; Okabayashi H; Akaike K; Hamada S; Masunaga A; Ichiyasu H; Sakagami T
    Respir Investig; 2024 May; 62(3):317-321. PubMed ID: 38395006
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Nintedanib for the treatment of systemic sclerosis-associated interstitial lung disease.
    Yamasaki Y; Kuwana M
    Expert Rev Clin Immunol; 2020 Jun; 16(6):547-560. PubMed ID: 32506975
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Rituximab therapy is more effective than cyclophosphamide therapy for Japanese patients with anti-topoisomerase I-positive systemic sclerosis-associated interstitial lung disease.
    Ebata S; Yoshizaki A; Fukasawa T; Miura S; Takahashi T; Sumida H; Asano Y; Sato S
    J Dermatol; 2019 Nov; 46(11):1006-1013. PubMed ID: 31502326
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Nintedanib: A Review in Fibrotic Interstitial Lung Diseases.
    Lamb YN
    Drugs; 2021 Apr; 81(5):575-586. PubMed ID: 33765296
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects and safety of rituximab in systemic sclerosis: an analysis from the European Scleroderma Trial and Research (EUSTAR) group.
    Jordan S; Distler JH; Maurer B; Huscher D; van Laar JM; Allanore Y; Distler O;
    Ann Rheum Dis; 2015 Jun; 74(6):1188-94. PubMed ID: 24442885
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and safety of nintedanib in patients with systemic sclerosis-associated interstitial lung disease treated with mycophenolate: a subgroup analysis of the SENSCIS trial.
    Highland KB; Distler O; Kuwana M; Allanore Y; Assassi S; Azuma A; Bourdin A; Denton CP; Distler JHW; Hoffmann-Vold AM; Khanna D; Mayes MD; Raghu G; Vonk MC; Gahlemann M; Clerisme-Beaty E; Girard M; Stowasser S; Zoz D; Maher TM;
    Lancet Respir Med; 2021 Jan; 9(1):96-106. PubMed ID: 33412120
    [TBL] [Abstract][Full Text] [Related]  

  • 12. An update on targeted therapies in systemic sclerosis based on a systematic review from the last 3 years.
    Campochiaro C; Allanore Y
    Arthritis Res Ther; 2021 Jun; 23(1):155. PubMed ID: 34074331
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Non-infectious pulmonary complications of newer biological agents for rheumatic diseases--a systematic literature review.
    Hadjinicolaou AV; Nisar MK; Bhagat S; Parfrey H; Chilvers ER; Ostör AJ
    Rheumatology (Oxford); 2011 Dec; 50(12):2297-305. PubMed ID: 22019799
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rituximab in the treatment of patients with systemic sclerosis. Our experience and review of the literature.
    Giuggioli D; Lumetti F; Colaci M; Fallahi P; Antonelli A; Ferri C
    Autoimmun Rev; 2015 Nov; 14(11):1072-8. PubMed ID: 26209905
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The effect of nintedanib versus mycophenolate mofetil in the Fra2 mouse model of systemic sclerosis-associated interstitial lung disease.
    Wollin L; Trinh-Minh T; Zhang Y; Distler JHW
    Clin Exp Rheumatol; 2021; 39 Suppl 131(4):134-141. PubMed ID: 33886452
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antifibrotic efficacy of nintedanib in a cellular model of systemic sclerosis-associated interstitial lung disease.
    Atanelishvili I; Akter T; Noguchi A; Vuyiv O; Wollin L; Silver RM; Bogatkevich GS
    Clin Exp Rheumatol; 2019; 37 Suppl 119(4):115-124. PubMed ID: 31573469
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Use of biologics for systemic sclerosis and systemic sclerosis-associated interstitial lung disease: Information from a Japanese hospital claims database.
    Narita Y; Funatogawa T; Mii K; Adachi H; Tamura A; Yamakido S
    Mod Rheumatol; 2023 Apr; 33(3):525-532. PubMed ID: 35652700
    [TBL] [Abstract][Full Text] [Related]  

  • 18. New Era in Systemic Sclerosis Treatment: Recently Approved Therapeutics.
    Ebata S; Yoshizaki-Ogawa A; Sato S; Yoshizaki A
    J Clin Med; 2022 Aug; 11(15):. PubMed ID: 35956246
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Real life data on nintedanib safety: idiopathic pulmonary fibrosis versus systemic sclerosis-interstitial lung disease and strategies adopted to manage adverse effects.
    Di Battista M; Tavanti L; Pistelli F; Carrozzi L; Da Rio M; Rossi A; Puccetti L; Tavoni A; Romei C; Morganti R; Della Rossa A; Mosca M
    Inflammopharmacology; 2023 Oct; 31(5):2445-2449. PubMed ID: 37535212
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and Safety of Nintedanib in Patients with Interstitial Lung Disease with or without Systemic Sclerosis: A Meta-Analysis.
    Lee YH; Song GG
    Iran J Public Health; 2023 Sep; 52(9):1781-1787. PubMed ID: 38033836
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.